Balancing Benefits, Guidelines, and Resistance: EGFR TKIs in NSCLC

This segment examines the strengths and limitations of tyrosine kinase inhibitors (TKIs) in the management of EGFR-mutated non–small cell lung cancer (NSCLC). Panelists will discuss the clinical benefits of EGFR TKIs, including targeted efficacy, improved response rates, and favorable quality-of-life outcomes, while also addressing challenges such as acquired resistance, adverse event management, and sequencing of therapy. The discussion will incorporate NCCN guideline recommendations, highlighting how TKIs are positioned across lines of therapy and disease settings. In addition, the evolving role of the pharmacist will be emphasized, particularly in monitoring treatment response, identifying early signs of resistance, managing drug-related toxicities, and supporting adherence. Together, these perspectives underscore the multidisciplinary approach required to optimize outcomes for patients receiving EGFR-targeted therapies.